Dr. Agarwal's Health Care IPO Funds Used As Planned, ICRA Confirms

Dr. Agarwal's Health Care Ltd has confirmed its Initial Public Offering (IPO) proceeds were used in line with its stated objectives for the quarter ending March 31, 2026. ICRA Limited, the appointed monitoring agency, reviewed the company's fund utilization and found no deviations.

The total IPO issue size was reported as ₹3,027.26 Crore. Separately, specific figures for the IPO period in FY25 indicated an issue size of ₹300.00 Crore (excluding OFS), with net proceeds of ₹272.47 Crore after expenses.

As of March 31, 2026, ICRA confirmed that ₹276.86 Crore of IPO proceeds had been utilized. Of this amount, ₹195.00 Crore was directed towards repayment or prepayment of borrowings. General corporate purposes accounted for the remaining ₹69.21 Crore of utilization by that date.

ICRA's report explicitly stated "No deviation observed" and "No comments" on the key checks regarding fund deployment.

This verification provides investors with assurance regarding Dr. Agarwal's Health Care's financial stewardship and adherence to its fundraising plans. The company, a specialist in ophthalmology, launched its IPO in January 2025, primarily aiming to repay borrowings and fund general corporate activities.

While direct listed peers focusing solely on eye care are limited, Dr. Agarwal's operates in the broader healthcare sector. Companies such as Apollo Hospitals Enterprise Ltd and Narayana Hrudayalaya Ltd also manage substantial capital deployment for their growth and operations. For all listed healthcare entities, ensuring IPO funds are used as planned is a critical step for sustainable growth.

Investors will likely monitor the deployment of the remaining unutilized IPO funds, which stood at ₹23.14 Crore as of March 31, 2026. Future reports from the monitoring agency and performance metrics demonstrating the contribution of these funds to business growth will be key areas to watch.